{"id":7704,"date":"2026-01-29T22:29:43","date_gmt":"2026-01-29T21:29:43","guid":{"rendered":"https:\/\/beonemedaffairs.com\/us\/?p=7704"},"modified":"2026-02-12T22:32:22","modified_gmt":"2026-02-12T21:32:22","slug":"zanubrutinib-for-the-treatment-of-patients-with-del17p-and-or-tp53-cll-sll-infographic","status":"publish","type":"post","link":"https:\/\/beonemedaffairs.com\/us\/7704\/zanubrutinib-for-the-treatment-of-patients-with-del17p-and-or-tp53-cll-sll-infographic\/","title":{"rendered":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL (infographic)"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":4581,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"editor_notices":[],"footnotes":""},"categories":[4],"post-tag":[],"specialisation":[],"class_list":["post-7704","post","type-post","status-publish","format-standard","hentry","category-reading"],"acf":{"visible_for_guests":false,"title":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL (infographic)","card_title":"Zanubrutinib for the treatment of patients with del(17p) and\/or TP53 CLL\/SLL (infographic)","title_for_guests":"","summary":"","card_summary":"","summary_for_guests":"","show_popup_window_to_guests":true,"blur_thumbnail_for_guests":false,"text_app":"Patients with CLL\/SLL with del(17p) and\/or TP53 mutations represent a high-risk population with a historically poor prognosis. Zanubrutinib, a highly potent and selective BTKi, has been evaluated in patients with CLL\/SLL, including those with del(17p) and\/or TP53-mutated CLL\/SLL, in various clinical studies such as SEQUOIA (NCT03336333), ALPINE (NCT03734016), and AU-003 (NCT02343120). Data from TN and R\/R patients with CLL\/SLL who harbor del(17p) and\/or TP53 mutations in SEQUOIA, ALPINE, and AU-003 were analyzed\u2014the largest evaluation to date in this population\u2014to assess the efficacy and safety of zanubrutinib. <a href=\"https:\/\/doi.org\/10.1182\/bloodadvances.2025015986\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1182\/bloodadvances.2025015986<\/a>","text":"Patients with CLL\/SLL with del(17p) and\/or TP53 mutations represent a high-risk population with a historically poor prognosis. Zanubrutinib, a highly potent and selective BTKi, has been evaluated in patients with CLL\/SLL, including those with del(17p) and\/or TP53-mutated CLL\/SLL, in various clinical studies such as SEQUOIA (NCT03336333), ALPINE (NCT03734016), and AU-003 (NCT02343120). Data from TN and R\/R patients with CLL\/SLL who harbor del(17p) and\/or TP53 mutations in SEQUOIA, ALPINE, and AU-003 were analyzed\u2014the largest evaluation to date in this population\u2014to assess the efficacy and safety of zanubrutinib. <a href=\"https:\/\/doi.org\/10.1182\/bloodadvances.2025015986\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1182\/bloodadvances.2025015986<\/a>","content-type":4,"download_file_reading":null,"display_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2026\/01\/25-BGP-MT-6819-HR-Infographic-L5-2.pdf","download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","motionposter":false,"webcast":"","videolange":null,"fliphtml_link":"","authors":[7708],"specialisation":[],"tags":[],"visible_tags":[],"post_image":7706,"post_image_for_guests":"","related_posts":[{"id":7515,"title":"Efficacy of Zanubrutinib Versus Acalabrutinib for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison","title_guest":"","summary":"","summary_guest":"","content-type":4,"post_image":7516,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7515\/efficacy-of-zanubrutinib-versus-acalabrutinib-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-a-matching-adjusted-indirect-comparison\/","date":"2025-09-22T12:23:13","date_gmt":"2025-09-22T10:23:13"},{"id":7479,"title":"BG-68501-101 Trial","title_guest":"","summary":"BG-68501-101 (NCT06257264) is a first-in-human, Phase 1a\/1b, open-label, dose-escalation and expansion trial evaluating BG-68501, a selective CDK2 inhibitor, as monotherapy and in combination with fulvestrant with or without BGB-43395 in patients with advanced, nonresectable, or metastatic solid tumors, including HR+\/HER2- breast cancer.","summary_guest":"","content-type":4,"post_image":7480,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7479\/bg-68501-101-trial\/","date":"2025-08-08T11:03:40","date_gmt":"2025-08-08T09:03:40"},{"id":7476,"title":"BGB-43395-101 Trial","title_guest":"","summary":"BGB-43395-101 (NCT06120283) is a Phase 1a\/1b, open-label, dose-escalation and expansion trial of BGB-43395, a selective CDK4 inhibitor, as monotherapy and in combination with fulvestrant, letrozole, or elacestrant in patients with hormone receptor-positive (HR+)\/HER2-negative metastatic breast cancer and other advanced solid tumors.","summary_guest":"","content-type":4,"post_image":7477,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7476\/bgb-43395-101-trial\/","date":"2025-08-08T11:01:48","date_gmt":"2025-08-08T09:01:48"},{"id":7473,"title":"RATIONALE-306 Trial","title_guest":"","summary":"RATIONALE-306 (NCT03783442) is a global, Phase 3, randomized, double-blind, placebo-controlled trial assessing tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).","summary_guest":"","content-type":4,"post_image":7474,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7473\/rationale-306-trial\/","date":"2025-08-08T10:59:42","date_gmt":"2025-08-08T08:59:42"},{"id":7470,"title":"RATIONALE-305 Trial","title_guest":"","summary":"RATIONALE-305 (NCT03777657) is a randomized, double-blind, placebo-controlled, global Phase 3 study of tislelizumab combined with platinum and fluoropyrimidine chemotherapy compared to placebo combined with platinum and fluoropyrimidine chemotherapy as a first-line treatment for patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC).","summary_guest":"","content-type":4,"post_image":7471,"blur_thumbnail_guest":false,"post_image_guest":false,"videolange":null,"url":"https:\/\/beonemedaffairs.com\/us\/7470\/rationale-305-trial\/","date":"2025-08-08T10:57:46","date_gmt":"2025-08-08T08:57:46"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/7704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/users\/4581"}],"replies":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/comments?post=7704"}],"version-history":[{"count":3,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/7704\/revisions"}],"predecessor-version":[{"id":7712,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/posts\/7704\/revisions\/7712"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/7708"}],"acf:term":[{"embeddable":true,"taxonomy":"category","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/categories\/4"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/categories?post=7704"},{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7704"},{"taxonomy":"specialisation","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/specialisation?post=7704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}